Von Eschenbach Disappointed With Critical Path Progress
This article was originally published in The Pink Sheet Daily
FDA Commissioner tells Maryland biotech audience he wants FDA to be a bridge rather than a barrier to life science advances.
You may also be interested in...
Voluntary collaboration will help FDA develop quality standards for submission of microarray data.
Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.